Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Impact · against what's priced in

Werewolf Therapeutics (HOWL) is seeing positive momentum driven by upward earnings estimate revisions. This shift in sentiment and fundamental outlook likely acts as a near-term catalyst for the stock price.

HOWL+0.60: No priced-in read yet
In context: The stock has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting an upward trend in earnings estimates which typically drives institutional buying pressure.
Read from the article alone

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

healthcare
biotech
HOWL
earnings estimates
rating upgrade
strong buy

Search tags

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

What matters in this story

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

What matters in this story

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

How each ticker is affected

Track these names every morning.

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

What matters in this story

Next reads from the same story arc

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

What matters in this story

Next reads from the same story arc

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

How each ticker is affected

Track these names every morning.

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY